BIO Announces Presenting Companies for 12th Annual BIO Investor Forum

Speakers will provide fresh insight, investment opportunities in biotech sector.</p>

Washington, D.C. (Sept. 11, 2013) – The Biotechnology Industry Organization (BIO) today announced the initial list of presenting companies for the 12th Annual BIO Investor Forum, an international investor forum which explores investment trends and opportunities in life sciences.  The event focuses on early and mid-stage private as well as emerging public companies that are poised for growth in 2014. The event will take place October 8-9, 2013 at the Palace Hotel in San Francisco, California. 

“We have an incredibly exciting slate of companies lined up for this year’s BIO Investor Forum, with more than 100 companies already scheduled to present,” said Alan Eisenberg, Executive Vice President, Emerging Companies & Business Development at BIO. “Early investor registrations are currently up 33 percent for this year’s BIO Investor Forum, reflecting greatly increased investor interest in the biotech sector.”

Companies were chosen through a competitive screening process with input from BIO and the event’s advisory committee. The committee is comprised of members from top-tier firms focused on investing and banking in the life sciences industry in addition to executives from emerging and leading biotech and pharmaceutical companies.

The following companies will present at the 12th Annual BIO Investor Forum:


Alios BioPharma
Altheus Therapeutics
Ambrx, Inc.
AM-Pharma Holding BV
Aquinox Pharmaceuticals Inc.
Asuragen, Inc.
Auspex Pharmaceuticals, Inc.
Bellicum Pharmaceuticals
Blueprint Medicines
Cerecor, Inc.        
ContraFect Corp
CytomX Therapeutics
Dicerna Pharmaceuticals
EGEN, Inc.
Eleison Pharmaceuticals LLC
Elusys Therapeutics
Fate Therapeutics, Inc.
Forma Therapeutics
Generon (Shanghai) Corp. Ltd
Hua Medicine
Immune Design Co.
Jennerex Biotherapeutics
Labrys Biologics, Inc.
MabVax Therapeutics
MaxCyte, Inc.
Mirna Therapeutics
Opsona Therapeutics
OxThera AB
Polynoma LLC
Probiodrug AG
Protagonist Therapeutics
Proteon Therapeutics
S1 Biopharma
Spring Bank Pharmaceuticals
Syndax Pharmaceuticals
Theraclone Sciences, Inc.
Vivaldi Biosciences, Inc.


Ambit Biosciences
Atossa Genetics
Benitec Ltd.
Bio-Path Holdings
Catalyst Pharmaceutical Partners, Inc.
CG Pharmaceuticals, Inc.
Cipher Pharmaceuticals Ltd.
Conatus Pharmaceuticals, Inc.
Critical Outcome Technologies
Galena BioPharma, Inc.
Genesis Biopharma
GensPera, Inc.
Heat Biologics
Horizon Pharma
Innovus Pharma
International Stem Cell Corp.
La Jolla Pharmaceutical Company
Mast Therapeutics
Ocera Therapeutics, Inc.
OncoMed Pharmaceuticals
OxiGENE, Inc.
Palatin Technologies
Patrys Ltd.
RXi Pharmaceuticals
Sernova Corp
Sophiris Bio
Therapeutics MD
ZIOPHARM Oncology Inc.

In addition, the 12th annual BIO Investor Forum will again host Discovery Track presentations, which focus on companies that have raised less than $25M to date in seed or Series A financing rounds. Companies in this track are also first-time presenters and use biotechnology or related technologies for research and development of drug products or diagnostics. The following companies are scheduled to present in the Discovery Track:

America Stem Cell
Applied Integrin Sciences
Armour Therapeutics
DiscoveryBioMed, Inc.
DLVR Therapeutics
EicOsis, LLC
Gemmus Pharma
GeneCentric Diagnostics
ImmunGene, Inc.
Kala Pharmaceuticals
Leading BioSciences
Maverix Biomics
Max BioPharma
Nanofiber Solutions
NovelMed Therapeutics
Numab AG
ScarX Therapeutics
Sensorion Pharmaceuticals
Sialix, Inc.
SironRX Therapeutics
Talon Pharmaceutical Services
Vascular Pharmaceuticals
viDA Therapeutics
Viking Therapeutics

New presenters are continuously being added. For updates on the list of presenting companies, please visit here. If you are interested in becoming a presenter, please submit an application here.

The BIO Investor Forum is the must-attend event for public and private market investors, research analysts, investment bankers, and industry executives focused on investment and business development opportunities in life sciences.  BIO One-on-One Partneringwill also provide an opportunity to arrange meetings between investors; companies; and industry business development, licensing and therapeutic franchise heads.

BIO is pleased to recognize the leadership provided by the BIO Investor Forum Conference sponsors including our Local Co-Host BayBio and Supporting Banks: Canaccord Genuity, Piper Jaffray and Roth Capital Partners. BIO Double Helix and Helix Sponsors include AbbVie, Amgen, Baxter, Janssen, and Merck. Conference supporters include Blaise Group International, Bristol-Myers Squibb, Chubb, Dectiva, Dentons, Fenwick & West LLP, Knobbe Martens, LaVoie Group, MacDougall Biomedical Communications and SecureDocs.

To learn more about the BIO Investor Forum, including registration and program information, please visit here. Registration is complimentary for credentialed members of the media and qualified investors.

Upcoming BIO Events 

BIO Investor Forum
October 8-9, 2013
San Francisco, CA

BIO IPCC Conference
November 6-8, 2013
Washington, DC

BIO Convention in China
November 11-13, 2013
Beijing, China

Pacific Rim Summit on Industrial Biotechnology & Bioenergy
December 8-11, 2013
San Diego, CA

BIO CEO & Investor Conference
February 10 – 11, 2014
New York, NY

BIO Asia International Conference
April 8-9, 2014
Tokyo, Japan

BIO International Convention
June 23-26, 2014
San Diego, CA